SCHEMBL11955393

SCHEMBL11955393

COc1ccc2cc1OCC/C=C\CCOc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 20/20 0.65
FLT3 P36888 20/20 0.65
JAK3 P52333 11/20 0.65
TYK2 P29597 8/20 0.65
CYP2D6 P10635 2/20 0.65
CDK2 P24941 14/20 0.63
JAK1 P23458 8/20 0.63
KCNH2 Q12809 1/20 0.63
CCNA2 P20248 12/20 0.63
CCNA1 P78396 12/20 0.63
GAK O14976 1/20 0.54
STK16 O75716 1/20 0.54
STK10 O94804 1/20 0.54
MAP4K4 O95819 1/20 0.54
PRKCB P05771 1/20 0.54
LCK P06239 1/20 0.54
CSF1R P07333 1/20 0.54
PDGFRB P09619 1/20 0.54
NQO2 P16083 1/20 0.54
FER P16591 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108240 0.90 JAK2 (0.82) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL1108237 0.90 JAK2 (0.82) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL18780727 0.84 JAK2 (0.60) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL18780731 0.84 JAK2 (0.60) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL1108236 0.83 JAK2 (0.87) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL1108245 0.83 JAK2 (0.87) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL14538672 0.81 JAK2 (0.79) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL14538675 0.81 JAK2 (0.79) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL1108286 0.81 JAK2 (0.81) JAK2FLT3JAK3TYK2CYP2D6
SCHEMBL17573432 0.80 JAK2 (0.67) JAK2FLT3JAK3TYK2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885JAK3 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.